Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs (Q44084905)

29 November 2017

title

Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs (English)

1 reference

29 November 2017

6

1 reference

29 November 2017

Tilo Senger

1

1 reference

29 November 2017

Lysann Schädlich

2

1 reference

29 November 2017

Sonja Textor

3

1 reference

29 November 2017

Corinna Klein

4

1 reference

29 November 2017

Kristina M Michael

5

1 reference

29 November 2017

Lutz Gissmann

7

1 reference

29 November 2017

language of work or name

English

0 references

publication date

8 December 2009

1 reference

29 November 2017

number of pages

11

1 reference

inferred from page(s)

published in

Vaccine

1 reference

29 November 2017

volume

28

1 reference

29 November 2017

issue

6

1 reference

29 November 2017

page(s)

1583-1593

1 reference

Classification of papillomaviruses

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Identification of an Immunologically Distinct Papillomavirus From Lesions of Epidermodysplasia Verruciformis 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

E6/E7 expression of human papillomavirus type 20 (HPV-20) and HPV-27 influences proliferation and differentiation of the skin in UV-irradiated SKH-hr1 transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Papillomavirus DNA in warts of immunosuppressed renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Benign human papillomavirus infection in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Vaccinations for Adult Solid-Organ Transplant Recipients: Current Recommendations and Protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

A long way: history of the prophylactic papillomavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Immunization with a pentameric L1 fusion protein protects against papillomavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Enhanced papillomavirus-like particle production in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Protein complex expression by using multigene baculoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Baculovirus expression system for heterologous multiprotein complexes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Baculovirus expression vectors: the requirements for high level expression of proteins, including glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Chimeric papillomavirus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Suppression of non-specific binding in serological Luminex assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Seroprevalence of 34 human papillomavirus types in the German general population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Efficient intracellular assembly of papillomaviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Carrageenan is a potent inhibitor of papillomavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Phylogenetic analysis of the human papillomavirus type 2 (HPV-2), HPV-27, and HPV-57 group, which is associated with common warts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Serological relationship between cutaneous human papillomavirus types 5, 8 and 92

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Reduced immunogenicity of diphtheria and tetanus toxoids when combined with pertussis toxoid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

Intercapsomeric disulfide bonds in papillomavirus assembly and disassembly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

7 January 2021

inferred from DOI database lookup

A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.048

7 January 2021

inferred from DOI database lookup

Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins

1 reference

12 December 2020

Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines

1 reference

12 December 2020

Degenerate and nested PCR: a highly sensitive and specific method for detection of human papillomavirus infection in cutaneous warts

1 reference

12 December 2020

Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin

1 reference

12 December 2020

Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles

1 reference

12 December 2020

Epidermodysplasia verruciformis: immunological and clinical aspects.

1 reference

12 December 2020

Human papillomaviruses in transplant-associated skin cancers

1 reference

12 December 2020

10.1016/J.VACCINE.2009.11.048

Identifiers

DOI

1 reference

29 November 2017

0 references

1 reference